{"id":528756,"date":"2021-02-04T06:06:01","date_gmt":"2021-02-04T06:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=528756"},"modified":"2021-02-04T06:06:01","modified_gmt":"2021-02-04T06:06:01","slug":"chronic-refractory-cough-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-refractory-cough-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_528756.html","title":{"rendered":"Chronic Refractory Cough Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast"},"content":{"rendered":"
\"Chronic<\/a><\/p>\n
\n
Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Chronic Refractory Cough Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Chronic Refractory Cough, historical and forecasted epidemiology as well as the Chronic Refractory Cough market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

Chronic refractory cough (CRC)<\/strong> is defined as a cough lasting more than 8 weeks that persists despite guidelines based treatment which may be treated by different medical specialities: Pulmonology, Allergy and Immunology, Digestive Health and Otorhinolaryngology.<\/p>\n

The diagnosis of Chronic Refractory Cough<\/strong> is either done by primary or secondary assessment. The initial assessment for protracted or chronic cough is intended to characterize the condition based on history, to elicit any alarm symptoms or findings that may indicate a serious underlying disease, and to identify whether there is a specific disease present that is associated with chronic cough. A second stage investigation is considered to further characterize the condition of the disease. These include nasendoscopy and 24 hour pH monitoring. <\/p>\n

There are currently no approved therapies for Chronic Refractory Cough<\/strong>. However, various off-label and over-the-counter medications are being used to treat the condition. These include neuromodulators, proton pump inhibitors, inhaled corticosteroids(ICs) and others.<\/p>\n

Get FREE sample copy at: <\/strong>
https:\/\/www.delveinsight.com\/sample-request\/chronic-refractory-cough-market<\/a><\/strong><\/p>\n

The Chronic Refractory Cough market<\/strong> report also covers emerging drugs, current treatment practices, Chronic Refractory Cough market share of the individual therapies, current and forecasted Chronic Refractory Cough Market Size from 2017 to 2030 segmented by seven major markets. <\/p>\n

The report provides a detailed current Chronic Refractory Cough treatment practice<\/strong>\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. <\/p>\n

\"Chronic<\/p>\n

Chronic Refractory Cough Market Key Facts<\/strong><\/p>\n

The total prevalent population of Chronic Cough<\/strong> in the 7 major markets was estimated to be 84,854,266 in 2020.<\/p>\n

The diagnosed prevalent population of CRC<\/strong> in the 7 MM is expected to increase at a CAGR of 0.48% during the forecast period.<\/p>\n

In the EU5 countries, the prevalent population of Chronic Cough<\/strong> was maximum in France with 8,799,771 cases, followed by the United Kingdom with 8,682,007 cases in 2020. While Spain accounted for the lowest diagnosed prevalent population of the indication with 5,708,813 cases in 2020.<\/p>\n

As per Delvelnsight’s analysis, Japan had 683,935 diagnosed prevalent cases of CRC<\/strong> in 2020.<\/p>\n

In the United States, the total prevalent cases of Chronic Cough<\/strong> consisted of 10,805,114 males and 29,213,828 females in 2020.<\/p>\n

Key Benefits of Chronic Refractory Cough Market Report<\/strong><\/p>\n